EP1306367A4 - Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten - Google Patents

Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten

Info

Publication number
EP1306367A4
EP1306367A4 EP01951935A EP01951935A EP1306367A4 EP 1306367 A4 EP1306367 A4 EP 1306367A4 EP 01951935 A EP01951935 A EP 01951935A EP 01951935 A EP01951935 A EP 01951935A EP 1306367 A4 EP1306367 A4 EP 1306367A4
Authority
EP
European Patent Office
Prior art keywords
sulfonic acid
acid derivatives
medical products
hydroxamic acids
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01951935A
Other languages
English (en)
French (fr)
Other versions
EP1306367A1 (de
EP1306367B1 (de
Inventor
Kazuhiro Maeda
Shuji Sonda
Tadahiro Takemoto
Tomokazu Goto
Fujio Kobayashi
Masahiko Kajii
Naruyasu Komorita
Fumihiro Hirayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of EP1306367A1 publication Critical patent/EP1306367A1/de
Publication of EP1306367A4 publication Critical patent/EP1306367A4/de
Application granted granted Critical
Publication of EP1306367B1 publication Critical patent/EP1306367B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
    • C07C309/09—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing etherified hydroxy groups bound to the carbon skeleton
    • C07C309/11—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing etherified hydroxy groups bound to the carbon skeleton with the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/51—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01951935A 2000-07-19 2001-07-19 Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten Expired - Lifetime EP1306367B1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000219245 2000-07-19
JP2000219034 2000-07-19
JP2000219034 2000-07-19
JP2000219245 2000-07-19
PCT/JP2001/006275 WO2002006214A1 (en) 2000-07-19 2001-07-19 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products

Publications (3)

Publication Number Publication Date
EP1306367A1 EP1306367A1 (de) 2003-05-02
EP1306367A4 true EP1306367A4 (de) 2004-06-09
EP1306367B1 EP1306367B1 (de) 2007-07-18

Family

ID=26596313

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01951935A Expired - Lifetime EP1306367B1 (de) 2000-07-19 2001-07-19 Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten

Country Status (9)

Country Link
US (1) US6989401B2 (de)
EP (1) EP1306367B1 (de)
KR (1) KR100799192B1 (de)
CN (1) CN1215052C (de)
AT (1) ATE367374T1 (de)
AU (1) AU2001272761A1 (de)
CA (1) CA2415954A1 (de)
DE (1) DE60129442T2 (de)
WO (1) WO2002006214A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
WO2004085396A1 (ja) * 2003-03-26 2004-10-07 Mitsubishi Pharma Corporation 虚血再灌流障害の予防または治療剤、臓器保存剤およびスクリーニング方法
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
AU2004264265C1 (en) 2003-08-14 2012-06-28 Thrombogenics Nv Antibodies against factor VIII with modified glycosylation in the variable region
JPWO2005037265A1 (ja) * 2003-10-17 2006-12-28 三菱ウェルファーマ株式会社 併用薬剤
CA2546024A1 (en) * 2003-11-17 2005-06-02 Wyeth Processes for the preparation of n-substituted phthalimides
US8574863B2 (en) 2004-02-04 2013-11-05 Pharmaaware Sepsis B.V. Alkaline phosphatase for treating an inflammatory disease of the gastro-intestinal tract
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CN101600730B (zh) * 2006-10-12 2014-01-29 Bhi有限合资公司 递送3-氨基-1-丙磺酸的方法、化合物、组合物和载体
WO2014015235A2 (en) * 2012-07-20 2014-01-23 Academia Sinica 3,5,n-trihydroxy-alkanamide and derivatives: method for making same and use thereof
CN111778228A (zh) 2014-01-24 2020-10-16 安-法玛公司 嵌合型碱性磷酸酶样蛋白
CA2936829C (en) 2014-01-24 2024-05-28 Am-Pharma B.V. Downstream processing of an alkaline phosphatase
TWI781145B (zh) * 2017-02-28 2022-10-21 美商伊繆諾金公司 具有自分解肽連接子之類美登素衍生物及其結合物
JP7714224B2 (ja) * 2022-01-21 2025-07-29 ステラファーマ株式会社 ボロノフェニルアラニンアミド誘導体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061642A1 (en) * 1998-05-27 1999-12-02 Cell Genesys, Inc. Recombinant aav vectors for gene therapy of hemophilia a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
ATE169621T1 (de) 1993-03-16 1998-08-15 British Biotech Pharm Hydroxamsaeurederivate als metalloproteinase inhibitoren
JPH07157470A (ja) 1993-03-18 1995-06-20 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
WO1996033968A1 (en) * 1995-04-25 1996-10-31 Fuji Yakuhin Kogyo Kabushiki Kaisha Highly water-soluble metalloproteinase inhibitor
EP1081132B1 (de) * 1998-05-22 2004-03-10 Mitsubishi Pharma Corporation Hydroxamsäurederivate und ihre medizinische anwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061642A1 (en) * 1998-05-27 1999-12-02 Cell Genesys, Inc. Recombinant aav vectors for gene therapy of hemophilia a

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LÄHDESMÄKI ET AL.: "Non-coded biosynthesis of N-acetylaspartyl peptides in mouse brain homogenates", JOURNAL OF LIQUID CHROMATOGRAPHY, vol. 5, no. 5, 1982, pages 989 - 1002, XP009029260 *

Also Published As

Publication number Publication date
DE60129442T2 (de) 2008-04-17
CA2415954A1 (en) 2003-01-17
WO2002006214A1 (en) 2002-01-24
ATE367374T1 (de) 2007-08-15
US20030176486A1 (en) 2003-09-18
EP1306367A1 (de) 2003-05-02
DE60129442D1 (de) 2007-08-30
KR20030029628A (ko) 2003-04-14
US6989401B2 (en) 2006-01-24
CN1443158A (zh) 2003-09-17
AU2001272761A1 (en) 2002-01-30
CN1215052C (zh) 2005-08-17
EP1306367B1 (de) 2007-07-18
KR100799192B1 (ko) 2008-01-31

Similar Documents

Publication Publication Date Title
EA200300065A1 (ru) Окисленные сложные эфиры 4-йодфениламинобензгидроксамовых кислот
EP1306367A4 (de) Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten
IS6859A (is) Kristölluð form atorvastatíns
PT1004578E (pt) Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
ATE297203T1 (de) Antithrombotische mitteln
PL396946A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
ATE306261T1 (de) Antithrombosemittel
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
FI950309A0 (fi) Proliiniamidijohdannaisia
WO2001019776A3 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
EP1184388A4 (de) Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon
EA200401114A3 (ru) Замещённые гидроксиэтиламины
EE04564B1 (et) Bifenlamidiini derivaadid, eelravim, vere koagulatsiooniinhibiitor ning proflaktiline ja terapeutiline toimeaine tromboosi v?i emboolia vastu
BR9905981A (pt) Compostos isocromano e processos para a sua produção.
HUP0201083A2 (hu) Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
ATE308540T1 (de) Antithrombosemittel
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
BR0314860A (pt) Derivados de pirazol
BR0208999A (pt) Processo para a preparação de ácido de cefpodoxima
DK1180094T3 (da) Kondenserede polycykliske aminosyrer som farmaceutiske midler

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030212

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MITSUBISHI PHARMA CORPORATION

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/40 B

Ipc: 7A 61K 31/4035 B

Ipc: 7A 61P 39/02 B

Ipc: 7C 07C 309/11 A

Ipc: 7A 61P 31/04 B

Ipc: 7C 07C 309/51 B

Ipc: 7C 07C 233/00 B

Ipc: 7A 61K 31/185 B

Ipc: 7A 61P 29/00 B

Ipc: 7C 07C 309/15 B

Ipc: 7C 07D 209/48 B

Ipc: 7A 61P 43/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20040426

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/185 B

Ipc: 7A 61P 31/04 B

Ipc: 7A 61K 31/40 B

Ipc: 7C 07C 309/11 A

Ipc: 7C 07C 233/00 B

Ipc: 7A 61P 29/00 B

Ipc: 7A 61P 43/00 B

Ipc: 7C 07D 209/48 B

Ipc: 7C 07K 5/00 B

Ipc: 7A 61K 31/4035 B

Ipc: 7C 07C 309/51 B

Ipc: 7A 61P 39/02 B

Ipc: 7C 07C 309/15 B

17Q First examination report despatched

Effective date: 20050225

17Q First examination report despatched

Effective date: 20050225

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SONDA, SHUJIMITSUBISHI PHARMA CORPORATION

Inventor name: KAJII, MASAHIKOMITSUBISHI PHARMA CORPORATION

Inventor name: KOMORITA,NARUYASUMITSUBISHI PHARMA CORPORATION

Inventor name: GOTO, TOMOKAZU

Inventor name: KOBAYASHI, FUJIOMUTSIBISHI PHARMA CORPORATION

Inventor name: TAKEMOTO, TADAHIROMITSUBISHI PHARMA CORPORATION

Inventor name: MAEDA, KAZUHIROMITSUBISHI PHARMA CORPORATION

Inventor name: HIRAYAMA,FUMIHIROMITSUBISHI PHARMA CORPORATION

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 60129442

Country of ref document: DE

Date of ref document: 20070830

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20070718

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071218

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071029

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071019

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20080421

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071018

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070719

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20080724

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080718

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080723

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070718

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1053829

Country of ref document: HK

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090719

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070731